{"filings":[{"id":667962,"accession_number":"0001213900-26-061028","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2026-05-26T20:15:40+00:00","items":["8.01"],"status":"ready","headline":"Neuphoria receives AUD 1.416M CTx CRC payment; eligible for ~4.65% of $460M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received AUD 1.416M from CTx CRC upon Pfizer's Phase III start in ER+/HER2- metastatic breast cancer.","Believes eligible for ~4.65% of future milestone payments from CTXT, total estimated at USD 460M across all parties.","Total distributions received from CTx CRC since 2016: AUD 3.52M.","Historical licensing revenues include AUD 967K from MSD (PRMT5) in 2016 and multiple Pfizer-related payments.","Company is a passive party and cannot determine whether future milestones will be achieved or payment amounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101975,"accession_number":"0001213900-26-002245","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"CEO Spyridon Papapetropoulos transitions to interim CEO under consulting agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment terminated Dec 31, 2025; Papapetropoulos remains on Board of Directors.","Consulting agreement effective Jan 1, 2026; $800/hr for up to ~40 hours/month.","Agreement terminates upon consummation of strategic transaction or after 12 months.","Severance includes annual base salary, target bonus, and medical premiums under prior employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118318,"accession_number":"0001213900-25-123289","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Neuphoria Therapeutics regains Nasdaq compliance after holding 2025 annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on July 18, 2025 for failing to hold annual meeting within 12 months of FY end (Rule 5620(a)).","Held 2025 annual shareholder meeting on December 12, 2025, satisfying the compliance requirement.","Nasdaq confirmed on December 18, 2025 that the company has regained compliance; matter is closed.","Previously disclosed delisting risk related to meeting requirement is now resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118317,"accession_number":"0001213900-25-122777","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Neuphoria Therapeutics Announces Annual Meeting Voting Results; Elects Two Class I Directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Peter Miles Davies (759,850 votes for) and David Wilson (758,571) as Class I directors.","Ratification of Wolf & Company P.C. as auditor passed with 807,022 votes in favor.","Non-binding advisory vote on executive compensation approved with 726,184 votes for.","On frequency of advisory votes, three years received the most votes (585,857), though non-binding.","Approximately 39.76% of outstanding shares (937,447) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118316,"accession_number":"0001213900-25-102607","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Neuphoria adopts poison pill after investor accumulates >20%; launches strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan triggered if any entity acquires 15%+ beneficial ownership without board approval.","Adopted after an individual investor disclosed >20% ownership as of Oct 23, 2025.","Rights expire Oct 27, 2026; no dead-hand/slow-hand provisions.","Board also evaluating strategic alternatives to maximize stockholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118315,"accession_number":"0001213900-25-100371","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Neuphoria Phase 3 trial of BNC210 for social anxiety disorder fails primary endpoint; SAD program discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AFFIRM-1 Phase 3 trial did not meet primary endpoint of change in SUDS scores during speech challenge; secondary endpoints also not significant.","Company discontinues further development of SAD program; plans full strategic review of operations and portfolio by year-end.","Cash and equivalents $14.2M as of June 30, 2025; expected to fund operations through Q2 fiscal 2027.","Ongoing Merck partnership: MK-1167 in Phase 2 for Alzheimer's; Neuphoria eligible for up to $450M in milestone payments plus royalties.","Given prior chronic dosing data, Neuphoria will evaluate next steps for BNC210 in PTSD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134760,"accession_number":"0001213900-25-087950","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Nasdaq grants Neuphoria 180-day extension to hold annual meeting, cure listing deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq accepted compliance plan on Sept 10, 2025; new deadline Dec 29, 2025.","Deficiency for failure to hold annual meeting within 12 months of fiscal year end June 30, 2024.","Company plans to file 10-K by Sept 29, 2025, then proxy and hold meeting within extension.","No financial impact disclosed; listing remains under monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134759,"accession_number":"0001213900-25-065723","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Neuphoria receives Nasdaq deficiency notice for missing annual meeting; plans compliance plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 18, 2025 for failure to hold annual meeting within 12 months of fiscal year ended June 30, 2024.","Must submit compliance plan by September 1, 2025; if accepted, exception until December 29, 2025.","Company plans to hold 2025 annual meeting in November 2025, consistent with past practice.","Deficiency notice has no immediate impact on listing of NEUP common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151669,"accession_number":"0001213900-25-045970","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neuphoria Q1 update: BNC-210 Phase 3 topline due Q3 2025; cash runway into Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash runway extends into Q3 2026; no near-term financing risk stated.","Phase 3 AFFIRM-1 trial of BNC-210 for social anxiety disorder on track for topline readout in Q3 2025.","Partnered α7 nAChR PAM MK-1167 (Merck) in Phase 2 for Alzheimer's disease.","Phase 2b SYMPHONY trial for BNC-210 in PTSD planned after positive FDA End-of-Phase 2 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170517,"accession_number":"0001213900-25-003492","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Neuphoria Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with Minimum Bid Price Rule 5450(a)(1) on Jan 10, 2025.","Common stock (NEUP) closed at $1.00 or higher for 10 consecutive business days from Dec 24, 2024 to Jan 8, 2025.","Deficiency letter previously disclosed in July 2024; compliance deadline was Jan 7, 2025.","Matter is now closed; company avoids potential delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187518,"accession_number":"0001213900-24-112016","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","3.01","3.02","3.03","5.03","8.01","5.01","5.02","5.05","9.01"],"status":"ready","headline":"Neuphoria completes redomiciliation from Australia to Delaware; shares to trade under NEUP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Dec 23, 2024, Bionomics Ltd. became a wholly-owned subsidiary of Neuphoria; NEUP shares to trade on Nasdaq from Dec 24.","Exchange ratio: 1 Neuphoria share per 2,160 Bionomics shares or per 12 ADSs; options and warrants converted proportionally.","Board classified into three classes with staggered terms; Spyros Papapetropoulos CEO, Tim Cunningham CFO, Alan Fisher Chair.","Neuphoria adopted 2024 Equity Incentive Plan and new anti-takeover charter provisions (classified board, 66 2/3% supermajority, no written consent)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187517,"accession_number":"0001213900-24-109347","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court approves Bionomics' re-domiciliation; Neuphoria to list Dec 24 under NEUP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Supreme Court of NSW approved Scheme of Arrangement on Dec 16, 2024; scheme became legally effective after lodgment with ASIC.","Bionomics ADSs trade on Nasdaq through Dec 23, 2024; shareholders as of Dec 17 record date receive scheme consideration.","Neuphoria Therapeutics Inc. shares expected to begin trading on Nasdaq under \"NEUP\" on Dec 24, 2024.","Bionomics will become wholly-owned subsidiary of Neuphoria, re-domiciling from Australia to Delaware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187516,"accession_number":"0001213900-24-108436","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Bionomics shareholders approve re-domiciliation to U.S. via Neuphoria; 96% vote in favor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["96% of votes cast and 87% of shareholders present voted in favor of scheme to re-domicile from Australia to Delaware.","Supreme Court of New South Wales to consider approval at Dec 16 hearing; conditions include expert opinion unchanged.","Implementation expected on or about Dec 24, 2024; Neuphoria shares to trade on Nasdaq under symbol 'NEUP'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187515,"accession_number":"0001213900-24-100971","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bionomics enters $2M ATM offering with H.C. Wainwright, replaces prior $11.5M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed ATM agreement with H.C. Wainwright for up to $2 million in ADSs; 3.0% sales commission.","Prior $11.5M ATM program with Cantor Fitzgerald terminated before signing new agreement.","Shelf registration on Form S-3 filed Nov 18, 2024 (File No. 333-283306) for the offering.","Sales agent may sell ADSs on Nasdaq at market prices; no minimum required sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187514,"accession_number":"0001213900-24-095926","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bionomics announces amended exchange ratio for re-domicile merger; court approves Dec 12 meeting","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amended exchange ratio: 1 Neuphoria share per 2,160 Bionomics ordinary shares; 1 per 12 ADSs.","Supreme Court of New South Wales approved convening of shareholder meeting on Dec 12, 2024.","Bionomics has Nasdaq minimum bid price deficiency notice; expects compliance after scheme completion.","Re-domicile from Australia to Delaware; Neuphoria common stock to list on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187513,"accession_number":"0001213900-24-086918","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bionomics director Aaron Weaver resigns from board effective Oct 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Weaver resigned from Bionomics' Board of Directors on October 9, 2024.","Resignation does not involve any disagreement on operations, policies, or practices.","Weaver served on the board for four years; company thanked him and wished him well."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187512,"accession_number":"0001213900-24-084175","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bionomics to re-domicile from Australia to US via scheme of arrangement with Neuphoria","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders receive 1 Neuphoria share per 1,440 ordinary shares or per 8 ADSs; estimated post-domicile Nasdaq price ~$3.50.","Board unanimously recommends approval; shareholder vote expected late Nov 2024, implementation early Dec 2024.","Re-domicile driven by loss of foreign private issuer status, reduced compliance costs, and greater US investor access.","No material change to assets, management, operations, or strategy expected; structure designed to be tax-neutral."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204006,"accession_number":"0001213900-24-061529","cik":1191070,"company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bionomics receives Nasdaq bid price deficiency notice; has until Jan 7, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Bionomics on July 11, 2024 that its ADS bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until Jan 7, 2025) to regain compliance by maintaining $1.00 closing bid for 10 consecutive days.","If not cured by Jan 7, 2025, Bionomics may qualify for a second 180-day period by meeting other listing standards and announcing a reverse stock split plan.","Failure to cure or qualify for extension could result in delisting from The Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29158631.15733333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}